Experienced in Migraine with Brainstem Aura

Murray B. Urowitz

Room 1E-409, 399 Bathurst Street, 
Toronto, ON, CA 
Experienced in Migraine with Brainstem Aura
Room 1E-409, 399 Bathurst Street, 
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Murray Urowitz practices in Toronto, Canada. Mr. Urowitz is rated as an Experienced expert by MediFind in the treatment of Migraine with Brainstem Aura. His top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Glomerulonephritis, Osteonecrosis, and Kidney Transplant.

His clinical research consists of co-authoring 236 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Migraine with Brainstem Aura.

Gender
Male

Locations

Room 1E-409, 399 Bathurst Street, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
View 1 Less Clinical Trial

235 Total Publications

Towards a minimal core dataset for systemic lupus erythematosus studies.
Towards a minimal core dataset for systemic lupus erythematosus studies.
Journal: Lupus science & medicine
Published: March 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Urowitz's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile